| Mechanistic PBPK modelling to predict the advantage of the salt form of a drug when dosed with acid reducing agents SK Chirumamilla, VT Banala, M Jamei, DB Turner Pharmaceutics 13 (8), 1169, 2021 | 15 | 2021 |
| Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers JR Wedagedera, A Afuape, SK Chirumamilla, H Momiji, R Leary, ... CPT: Pharmacometrics & Systems Pharmacology 11 (6), 755-765, 2022 | 11 | 2022 |
| Assessing dose-exposure–response relationships of miltefosine in adults and children using physiologically-based pharmacokinetic modeling approach SJ Madu, K Wang, SK Chirumamilla, DB Turner, PG Steel, M Li Pharmaceutical research 40 (12), 2983-3000, 2023 | 1 | 2023 |
| Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn’s Disease Patients through PBPK Modeling C Han, T Sun, SK Chirumamilla, FY Bois, M Xu, A Rostami-Hodjegan Pharmaceutics 15 (9), 2237, 2023 | 1 | 2023 |
| Harnessing the power of IVIVE-PBPK to explore potential discordance between local gut vs systemic bioequivalence in health and disease: the case of budesonide in crohn’s disease C Han, SK Chirumamilla, T Sun, M Xu, F Bois, A Rostami-Hodjegan Drug Metabolism and Pharmacokinetics 55, 100970, 2024 | | 2024 |
| Harnessing the Power of Physiologically Based Pharmacokinetic Modeling to Explore Potential Discordance between in vitro Dissolution, Local Gut vs Systemic Bioequivalence in … C Han, T Sun, S Chirumamilla, F Bois, M Xu, A Rostami-Hodjegan Preprints, 2023 | | 2023 |
| Application of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients SK Chirumamilla, RH Rose, K Abduljalil, D Pade, C Liu, I Taneja, ... Population Approach Group Europe, 2019 | | 2019 |
| PBPK-Based Virtual Bioequivalence Trials to Guide Drug Development A Mitra, J Mullin, SK Chirumamilla The Art and Science of Physiologically-Based Pharmacokinetics Modeling, 180-214, 0 | | |
| I-03: Khaled Abduljalil Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice K Abduljalil, RH Rose, D Pade, SK Chirumamilla, C Liu, I Taneja, ... PAGE2019 Poster Abstracts, 19, 0 | | |
Frederic Y. BoisSenior Sci Advisor & Head of Mechanistic Modelling, Certara Simcyp divisionVerified email at certara.com